Inhalation device for producing a drug aerosol

Information

  • Patent Grant
  • 7913688
  • Patent Number
    7,913,688
  • Date Filed
    Tuesday, May 20, 2003
    21 years ago
  • Date Issued
    Tuesday, March 29, 2011
    13 years ago
Abstract
A device for delivering a drug by inhalation is disclosed. The device includes a body defining an interior flow-through chamber having upstream and downstream chamber openings, and a drug supply unit contained within the chamber for producing, upon actuation, a heated drug vapor in a condensation region of the chamber. Gas drawn through the chamber region at a selected gas-flow rate is effective to form drug condensation particles from the drug vapor having a selected MMAD between 0.02 and 0.1 MMAD or between 1 and 3.5 μm. A gas-flow control valve disposed upstream of the unit functions to limit gas-flow rate through the condensation region to the selected gas-flow rate. An actuation switch in the device activates the drug-supply unit, such that the drug-supply unit can be controlled to produce vapor when the gas-flow rate through the chamber is at the selected flow rate.
Description
FIELD OF THE INVENTION

The present invention relates to an inhalation device for producing desired-size drug-aerosol particles for inhalation.


BACKGROUND OF THE INVENTION

Therapeutic compounds may be administered by a variety of routes, depending on the nature of the drug, the pharmacokinetic profile desired, patient convenience, and cost, among other factors. Among the most common routes of drug delivery are oral, intravenous (IV), intramuscular (IM) intraperitoneal (IP) subcutaneous, transdermal, transmucosal, and by inhalation to the patient's respiratory tract.


The inhalation route of drug administration offers several advantages for certain drugs, and in treating certain conditions. Since the drug administered passes quickly from the respiratory tract to the bloodstream, the drug may be active within a few minutes of delivery. This rapid drug effect is clearly advantageous for conditions like asthma, anaphylaxis, pain, and so forth where immediate relief is desired.


Further, the drug is more efficiently utilized by the patient, since the drug is taken up into the bloodstream without a first pass through the liver as is the case for oral drug delivery. Accordingly, the therapeutic dose of a drug administered by inhalation can be substantially less, e.g., one half that required for oral dosing.


Finally, since inhalation delivery is convenient, patient compliance can be expected to be high.


As is known, efficient aerosol delivery to the lungs requires that the particles have certain penetration and settling or diffusional characteristics. For larger particles, deposition in the deep lungs occurs by gravitational settling and requires particles to have an effective settling size, defined as mass median aerodynamic diameter (MMAD), of between 1-3.5 μm. For smaller particles, deposition to the deep lung occurs by a diffusional process that requires having a particle size in the 10-100 nm, typically 20-100 nm range. Particle sizes that fall in the range between 10-100 nm and 1-3.5 μm tend to have poor penetration and poor deposition. Therefore, an inhalation drug-delivery device for deep lung delivery should produce an aerosol having particles in one of these two size ranges.


Another important feature of an aerosol delivery device is control over total dose delivered, that is, the amount of aerosol generated should be predictable and repeatable from one dosing to another.


Other desirable features for an inhalation device are good product storageability, without significant loss of drug activity.


It would therefore be desirable to provide an aerosol inhalation device that provides these features in a simple, easily operated inhalation device.


SUMMARY OF THE INVENTION

The invention includes a device for delivering a drug by inhalation or by nasal administration, in an aerosol form composed of drug-particles having desired sizes, typically expressed as mass median aerodynamic diameter (MMAD) of the aerosol particles. As used herein, an aerosol is a collection of tiny solid or liquid particles that are finely dispersed in a gas. The device includes a body defining an interior flow-through chamber having upstream and downstream chamber openings. A drug supply unit contained within the chamber is designed for producing, upon actuation, a heated drug vapor in a condensation region of the chamber adjacent the substrate and between the upstream and downstream chamber openings, such that gas drawn through the chamber region at a selected gas-flow rate is effective to condense drug vapor to form drug condensation particles having a selected MMAD particle size, for example, when used for deep-lung delivery, between 10-100 nm or between 1-3.5 μm. To this end, the device includes a gas-flow control valve disposed upstream of the drug-supply unit for limiting gas-flow rate through the condensation region to the selected gas-flow rate, for example, for limiting air flow through the chamber as air is drawn by the user's mouth into and through the chamber. Also included is an actuation switch for actuating the drug-supply unit, such that the unit can be controlled to produce vapor when the gas-flow rate through the chamber is at the selected flow rate or within a selected flow-rate range.


The actuation switch may activate the drug-supply unit such that the unit is producing vapor when the selected air-flow rate is achieved; alternatively, the actuation switch may activate the drug-supply unit after the selected air-flow rate within the chamber is reached.


In one general embodiment, the gas-flow valve is designed to limit the rate of air flow through the chamber, as the user draws air through the chamber by mouth. In a specific embodiment, the gas-flow valve includes an inlet port communicating with the chamber, and a deformable flap adapted to divert or restrict air flow away from the port increasingly, with increasing pressure drop across the valve. In another embodiment, the gas-flow valve includes the actuation switch, with valve movement in response to an air pressure differential across the valve acting to close the switch. In still another embodiment, the gas-flow valve includes an orifice designed to limit airflow rate into the chamber.


The device may also include a bypass valve communicating with the chamber downstream of the unit for offsetting the decrease in airflow produced by the gas-flow control valve, as the user draws air into the chamber.


The actuation switch may include a thermistor that is responsive to heat-dissipative effects of gas flow through the chamber. The device may further include a user-activated switch whose actuation is effective to heat the thermistor, prior to triggering of the drug-supply unit by the thermistor to initiate heating of the drug-supply unit.


The drug-supply unit may include a heat-conductive substrate having an outer surface, a film of drug formed on the substrate surface, and a heat source for heating the substrate to a temperature effective to vaporize said drug. The heat source, may be, for example, an electrical source for producing resistive heating of the substrate, or a chemical heat source for producing substrate heating by initiation of an exothermic reaction. Preferably, the drug delivery unit is effective to vaporize the film of drug, following actuation, within a period of less than 1 second, more preferably, within 0.5 seconds. As used herein, vaporize and vaporization refer to the transformation of solids or liquids into gases.


For producing condensation particles in the size range 1-3.5 μm MMAD, the chamber may have substantially smooth-surfaced walls, and the selected gas-flow rate may be in the range of 4-50 L/minute.


For producing condensation particles in the size range 20-100 nm MMAD, the chamber may provide gas-flow barriers for creating air turbulence within the condensation chamber. These barriers are typically placed within a few thousands of an inch from the substrate surface.


These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a simplified sectional view of an inhalation device constructed according to one embodiment of the invention;



FIGS. 2A and 2B are plots of airflow rates through the device of the invention, showing airflow through primary and secondary flow regions, and the desired timing relationship between airflow level and vaporization of drug;



FIG. 3 is a perspective, partially exploded view of the device shown in FIG. 1;



FIG. 4A is a plot of aerosol condensation particle size (MMAD) as a function of airflow rate in the absence of internal turbulence for an airflow chamber having a cross-section area of 1 cm2, and at airflow rates between 5 and 30 liters/minute; and FIG. 4B shows the fraction of alveolar deposition of aerosol particles as a function of particle size;



FIGS. 5A-5F illustrate different types of gas-flow valves suitable for use in the device of the invention;



FIGS. 6A-6C illustrate different types of actuation circuitry suitable for use in the device of the invention;



FIGS. 7A-7E are photographic reproductions showing the development of aerosol particles in the device over a period of about 500 msec; and



FIGS. 8A-8C show alternative airflow control configurations in the device of the invention.





DETAILED DESCRIPTION OF THE INVENTION


FIG. 1 is a simplified cross-sectional view of an inhalation device 20 for delivering a drug by inhalation. The device includes a body 22 defining an interior flow-through chamber 24 having upstream and downstream chamber openings 26, 28, respectively. A drug-supply unit 30 contained within the chamber is operable, upon actuation, to produce a heated drug vapor in a condensation region 32 of the chamber adjacent the substrate and between the upstream and downstream chamber openings. As will be detailed below, when gas is flowed across the surface of the drug-supply unit, with either laminar flow or with turbulence, at a selected velocity, the drug vapor condenses to form drug condensation particles having a selected MMAD particle size. As one of skill in the art would appreciate, the gas velocity through the chamber may be controlled by changing the volumetric gas-flow rate, cross-sectional area within the chamber, and/or the presence or absence of structures that produce turbulence within the chamber. For inhalation, two exemplary size ranges are between about 1 and 3.5 μm, and within 0.02 and 0.1 μm.


The device includes a gas-flow control valve 34 disposed in or adjacent the upstream opening of the chamber for limiting gas-flow rate through the chamber's condensation region to a selected gas-flow rate. Typically, the gas flowed through the chamber is air drawn through the chamber by the user's mouth, that is, by the user drawing air through the upstream end of the device chamber. Various types of gas-flow valves suitable for use in the invention are described below with respect to FIGS. 5A-5F.


Also included in the device is an actuation switch, indicated generally at 36, for actuating the drug-supply unit. The switch allows the drug-supply unit to be controlled to produce vapor when the air-flow rate through the chamber's condensation region is at the selected flow rate. As will be seen, the switch is typically actuated by air flow through the chamber, such that as the user draws air through the chamber, vapor production is initiated when air flow through the condensation region reaches the selected air flow rate for producing desired-size condensation particles. Various types of activation switches suitable for use in the invention are described below with respect to FIGS. 6A-6C.


In one general embodiment, the switch is constructed to activate the drug-supply unit prior to the gas-flow rate in the chamber reaching the selected rate. In this embodiment, the timing of actuation is such that the drug-supply unit begins its production of drug vapor at about the time or after the gas-flow through the chamber reaches its selected gas-flow flow rate. In another embodiment, the drug-supply unit is actuated when the gas-flow rate through the chamber reaches the selected flow rate. In yet another embodiment, the drug-supply unit is actuated at some selected time after the selected flow rate has been reached.


The condensation region in the device, where heated drug vapor is condensed to form desired-size aerosol particles, includes that portion of the chamber between the drug-supply unit and the interior wall of the chamber, and may include a portion of the chamber between the downstream end of the drug-supply unit and the downstream opening of the chamber. It is in this region where gas flow is controlled to a desired rate and thus velocity during aerosol formation.


As shown schematically in FIG. 1, drug-supply unit 30 in the device generally includes a heat-conductive substrate 38 having an outer surface 40, a film 42 of the drug to be administered formed on the substrate's outer surface, and a heat source 44 for heating the substrate to a temperature effective to vaporize the drug. In the embodiment illustrated, the substrate is a tapered cylindrical canister closed at its upstream end. A preferred material for the substrate is stainless steel, which has been shown to be acceptable for drug stability.


The drug film includes the drug to be administered either in pure form, or mixed with suitable excipients. Exemplary drugs suitable for use include any drugs that can be vaporized at a temperature typically between 250-560° C. The drug is preferably one that can be vaporized with little or no drug-degradation products. As has been reported in several co-owned applications, many classes of drugs can be successfully vaporized with little or no degradation, particularly where the drug coating has a selected film thickness between about 0.01 and 10 μm. The amount of drug present is preferably sufficient to provide a therapeutic dose, although the device may also be used to titrate a therapeutic dose by multiple dosing. The total area of the substrate on which the film is applied may be adjusted accordingly, so that the total amount of drug available for aerosol formation constitutes a therapeutic dose. Vaporization in typically less than 0.5 seconds is enabled by the thinness of the drug coating. Essentially, the thin nature of the drug coating exposes a large fraction of the heated compound to flowing air, resulting in almost the entire compound vaporizing and cooling in the air prior to thermal degradation. At film thicknesses used in the device, aerosol particles having less than 5% degradation products are produced over a broad range of substrate peak temperatures.


The heat source for vaporizing the drug may be a resistive heating element, for example, the substrate itself, or resistive wires placed against the interior surface of the substrate. Alternatively, and as shown in FIG. 1, heat source 44 is a chemically reactive material which undergoes an exothermic reaction upon actuation, e.g., by a spark or heat element. In the particular embodiment shown, actuation is produced by a spark supplied to the upstream end of the chemical material, igniting an exothermic reaction that spreads in a downstream to upstream direction within the drug-supply unit, that is, in the direction opposite the flow of gas within the chamber during aerosol formation. An exemplary chemical material includes a mixture of Zr and MoO3, at a weight ratio of about 75%:25%. The mixture may contain binders, such as polyvinyl alcohol or nitrocellulose, and an initiator comprising additives such as boron and KClO3, to control the reaction. In any case, and as mentioned above, the material should be formulated to produce complete heating over the substrate surface in a period of 2 sec or less, preferably in the range 10-500 msec.


An exemplary peak temperature of the surface of the drug-supply unit is 375° C. The temperature can be modified by changes in the fuel formulation. Because high drug purities are obtained at temperatures higher than those needed for complete vaporization, there may be a large window within which emitted dose and aerosol purity are both high and consistent.


As noted above, actuation switch 36 in the device is designed for actuating the drug-supply unit in relation to airflow through the device chamber, such that the drug-supply unit produces drug vapor when the air flow rate through the chamber is sufficient for producing desired-size aerosol particles. In one general embodiment, described below with respect to FIGS. 6A-6C, the switch is controlled by airflow through the chamber, such that the drug-supply unit is activated when (or just prior to, or after) the rate of airflow in the device reaches its desired rate. Alternatively, the switch may be user activated, allowing the user to initiate drug vapor formation as air is being drawn into the device. In the latter embodiment, the device may provide a signal, such as an audible tone, to the user, when the desired rate of airflow through the device is reached.


In the following discussion of gas-flow control through the device, it will be assumed that the gas being drawn through the device is air drawn in by the user's breath intake. However, it will be appreciated that the gas, or a portion therefore, might be supplied by a separate gas cartridge or source, such as a CO2 or nitrogen gas source. An inert or non-oxidizing gas may be desirable, for example, in the vaporization of a drug that is labile to oxidative breakdown at elevated temperature, that is, during vaporization. In this case, the “gas” breathed in by the user may be a combination of a pure gas supplied through the condensation region, and air drawn in by the user downstream of the condensation region, or may be just pure gas.


In the embodiment shown in FIG. 1, airflow between the upstream and downstream ends of the device is controlled by both gas-flow valve 34, which controls the flow of air into the upstream opening of the device, and hence through the condensation region of the chamber, and a bypass valve 46 located adjacent the downstream end of the device. The bypass valve cooperates with the gas-control valve to control the flow through the condensation region of the chamber as well as the total amount of air being drawn through the device.


In particular, and as seen in the air-flow plot in FIG. 2A, the total volumetric airflow through the device, indicated at I, is the sum of the volumetric airflow rate P through valve 34, and the volumetric airflow rate B through the bypass valve. Valve 34 acts to limit air drawn into the device to a preselected level P, e.g., 15 L/minute, corresponding to the selected air-flow rate for producing aerosol particles of a selected size. Once this selected airflow level is reached, additional air drawn into the device creates a pressure drop across valve 46 which then accommodates airflow through the valve into the downstream end of the device adjacent the user's mouth. Thus, the user senses a full breath being drawn in, with the two valves distributing the total airflow between desired airflow rate P and bypass airflow rate B.



FIG. 2A also indicates the timing of the heating for the drug-supply unit, wherein the time of heating is defined as the time during which sufficient heat is applies to the drug substance so as to cause rapid vaporization of the drug. As seen here, heating time, indicated by the hatched rectangle, is intended to occur within the period that the airflow P is at the desired airflow rate, for example, within the time period indicated at points a and b in the figure. It can be appreciated that if a user draws in more or less breath, the difference in airflow rate is accommodated by changes in B, with P remaining constant as long as I is greater than P.



FIG. 2B shows the same gas-distribution effect, but plotted as a series of flow profiles over five different time periods during operation of the device. As seen here, the gas-flow rate through the condensation region in the device, indicated at P in the figure, remains relatively constant, while total gas-flow rate, indicated at I increases over the first four time intervals, then decreases.


The linear velocity of airflow over the vaporizing drug affects the particle size of the aerosol particles produced by vapor condensation, with more rapid airflow diluting the vapor such that it condenses into smaller particles. In other words the particle size distribution of the aerosol is determined by the concentration of the compound vapor during condensation. This vapor concentration is, in turn, determined by the extent to which airflow over the surface of the heating substrate dilutes the evolved vapor. As shown in FIG. 4A below, the particle size (MMAD) remains well within an acceptable range (1-3.5 microns) at airflow rates from 7 L/min to 28 L/min through the drug product. To achieve smaller or larger particles, the gas velocity through the condensation region of the chamber may be altered by (i) modifying the gas-flow control valve to increase or decrease P, and/or (ii) modifying the cross-section of the chamber condensation region to increase or decrease linear gas velocity for a given volumetric flow rate.



FIG. 4B shows the fraction of alveolar deposition of aerosol particles as a function of particle size. As seen, maximum deposition into the lungs occurs in either of two size ranges: 1-3.5 μm or 20-100 nm. Therefore, where the device is employed for drug delivery by inhalation, the selected gas-flow rate in the device of a given geometry is such as to achieve aerosol particles sizes in one of these two size ranges. One skilled in the art will appreciate how changes in gas-flow velocity, to effect desired particle sizes, can be achieved by manipulating volumetric gas-flow rate, valve design and characteristics, cross-sectional area of the condensation region of the device, and, particularly where small particles are desired, placement of barriers within the chamber capable of producing turbulence that increases the dilution effect of gas flowing through the heated drug vapor.



FIG. 3 is an exploded view of device 20 illustrated in FIG. 1. Here the body of the device, indicated at 22, is formed of two molded plastic members 48, 50 which are sealed together conventionally. Bypass valves 46 are designed to be placed on either side of a downstream end region 52 of the device, when the two body members are sealed together. Member 48 includes an air inlet 56 through which air is drawn into the device chamber adjacent the upstream end of the device 54.


The drug-supply unit, air-intake valve, and actuation switch in the device are all incorporated into a single assembly 58. The parts of the assembly that are visible are the coated substrate 38, gas control valve 34, battery housing 36 and a pull tab (user-activated switch) 60 which extends through an opening at the upstream end of the device body in the assembled device. An outer flange 62 in the assembly is designed to fit in a groove 64 formed on the inner wall of each member, partitioning the chamber into upstream and downstream chamber sections 66, 68, respectively. The flange has openings, such as opening 70, formed on its opposite sides as shown, with each opening being gated by a gas-flow valve, such as valve 34, for regulating the rate of airflow across the valves. Thus, when air is drawn into the device by the user, with the user's mouth on the upstream device end, air is drawn into the device through intake 56 and into section 66. Valve 34 then regulates airflow between the two chamber sections, as will be described below with reference to FIGS. 5A-5F, to limit airflow across the drug-supply device to the desired airflow rate P.


Turning to various gas-flow valve embodiments suitable for the invention, FIG. 5A shows an umbrella valve 70. This valve is a low-durometer rubber member 71 that flexes out of the way to allow air to enter when the difference in pressure inside and outside of the airway (between the upstream and downstream chamber sections). This valve thus functions to “open” in response to an air pressure differential across the valve, and is constructed so that the valve limits airflow to the desired airflow rate in the device.



FIG. 5B illustrates a reed valve 72 that includes two low-durometer rubber pieces 74 that are held together by a biasing member 76 (such as a spring). When the air-pressure across the two chamber sections reaches a selected differential, the two rubber pieces pull apart to create an opening for air to flow into the airway. Like valve 70, this valve thus functions to “open” in response to an air pressure differential across the valve, and is constructed so that the valve limits airflow to the desired airflow rate in the device.



FIGS. 5C and 5D illustrate a valve 80 that bends in response to a pressure differential across the chamber sections to let air into the airway. Specifically, FIG. 5C illustrates this valve in an extended closed position that does not allow any air into the airway. One end portion of the valve is rigidly attached to a side of a valve opening 84, with the opposite side of the valve terminating against the side of an air-inlet opening 85. When the difference in pressure between the inside and outside of the airway passes a threshold level, the valve 80 bends at its center, and rotates into the airway about the portion that stays rigidly attached to the airway, as shown in FIG. 5D, creating the airway to create an orifice for air to flow through the valve opening.


In construction, the lower flexing layers at 86 are formed of flexible polymer plate material, while the upper short layers at 88 are formed of an inflexible polymer material. Also as shown, the valve may include electrical contacts, such as contact 90, that are brought into a closed circuit configuration when the valve is moved to its open, deformed condition. Like the two valves above, valve 80 functions to “open” in response to an air pressure differential across the valve, and is constructed so that in the open condition, the valve limits airflow to the desired airflow rate in the device.


The electrical switch in the valve may serve as a switching member of the actuation switch, so that opening of the valve also acts to actuate the drug-supply unit. The present invention contemplates a gas-control valve that includes an electrical switch that is moved from an open to closed condition, when the valve is moved to a condition that admits airflow at the selected desired rate.



FIGS. 5E and 5F illustrate a valve 92 that moves from an open toward a partially closed condition as air is drawn into the device. The valve includes a curved screened opening 94 having a generally circular-arc cross section. A deformable valve flap 96 attached as shown at the top of the valve is designed to move toward opening 94 as the pressure differential across the valve increases, effectively closing a portion of the valve opening as the air differential increases. The deformability of the flap, in response to an air pressure differential across the valve, is such as to maintain the desired air flow rate P through the valve substantially independent of the pressure differential across the valve. The valve differs from those described above in that the valve is initially in an open condition, and moves progressively toward a closed condition as the pressure differential across the valve increases.


It will be appreciated that the bypass valve in the device may have the same general construction as one of the valves noted above, particular those valves that are designed to open when a pressure differential is applied across the valve. The gas-control and bypass valves are designed so that initial pressure differential across the valves, when the user begins drawing air into the device, is effective to first establish the desired flow rate P through the condensation region in the device. Once this flow rate is established, additional flow rate B applied by the user is effective to “open” the bypass valve to allow bypass airflow into the device. Since air is being drawn through the device along both airflow paths, the user is unaware of the bifurcation of airflow that occurs.


Exemplary actuation switches and associated circuitry suitable for use in the invention are illustrated in FIGS. 6A-6C. FIG. 6A illustrates a circuit 100 having a trigger switch 98 that is connected between a voltage source 99 and microcontroller 102. The trigger switch may be a valve-actuated switch, as above, or a user activated switch that is activated during air intake. When the trigger switch opens, the microcontroller no longer receives the voltage from the voltage source. Accordingly, the microcontroller senses the trigger event, and starts to measure (e.g., starts a timer) the time that the trigger event lasts. If this trigger event lasts at least the threshold time period tth, the microcontroller closes a second switch 104 for a pulsing time interval tp. This closing causes current flow from the voltage source to a resistor 106 that is effective to either heat the drug-substrate by resistive heating or to heat-initiate an exothermic reaction in the drug-supply unit, shown at 108.



FIG. 6B illustrates another circuit 110 that can be used for actuating the drug-supply unit, in accordance with the invention. This circuit is similar to circuit 100, except that it operates to pass a charge from a capacitor 112 to substrate 108. The capacitor is typically charged by voltage source 99. The microcontroller 102 closes the normally open switch 113 when it detects that switch 98 has remained open for a threshold time period. The closing of switch 113 transfers the charge from capacitor 112 to ground through the substrate. The transferred charge is used either to heat the substrate resistively, or to initiate an exothermic reaction in the drug-supply unit as above.


Another exemplary actuation switch is illustrated at 114 in FIG. 6C. This switch has a user-activated component which readies the switch for use shortly before use, e.g., an air-flow responsive component that activates the drug-supply unit when the desired air-flow rate is achieved. The user-activated component is a pull-tab switch 116 that is activated when the user pulls a tab (tab 60 in the device illustrated in FIG. 3). When switch 116 is closed, voltage source 118 is connected to a thermistor 122 which is then heated to a temperature above ambient. The thermistor is connected to a voltage comparator 120, such as a Seiko S-8143 comparator available from Seiko. The comparator functions to measure the thermistor voltage output at a time shortly after the user switch is activated. When a user then begins to draw air across the thermistor, the airflow cause the thermistor to cool, generating a different voltage output (by the thermistor). When the difference in these voltages reaches a predetermined threshold, the comparator signals a solid-state switch 124 to close, producing current flow to drug-supply unit 108 from voltage source 118, and activation of the unit. The heating of the thermistor and comparator threshold are adjusted such that switch 124 is closed when the air flow rate through the device reaches a desired airflow rate.


The series of photographic reproductions in FIGS. 7A-7D illustrate the time sequence of production of drug condensate during operation of the device of the invention. At time 0 (FIG. 7A) when the drug-supply unit is first actuated, air flow is established across the surface of the substrate, but no vapor has yet been formed. At 50 msec (FIG. 7B), some condensate formation can be observed downstream of the substrate. The amount of condensate being formed increases up to about 200 msec, but is still being formed at 500 msec, although the majority of condensate has been formed in the first 500 msec.



FIGS. 8A-8C illustrate alternative device embodiments for distributing airflow through the device during operation. In FIG. 8A, a device 126 includes an upstream opening 130 containing an airflow sensor 132, such as the thermistor described above, which is responsive to airflow through the opening. Air flow drawn into a central chamber 134 by the user through opening 130 is valved, to achieve a selected flow rate, by gas-flow control valve(s) 138. Excess airflow is diverted to the downstream end region of the chamber via a bypass channel 136 extending between the upstream and downstream ends of the device, and communicating with central chamber 134 through a valve 127. The orifice is so dimensioned that drawing air into the device creates an initial pressure differential across valve 138, so that airflow through the central chamber reaches the desired airflow rate, with excess air being diverted through the bypass orifice.


A device 142 shown in FIG. 8B has a similar airflow configuration, but differs from device 126 in having only a single valve 143 which functions to admit air into a central chamber 144 until a desired airflow rate is achieved, then divert excess air into a bypass channel 145 that communicates with the downstream end of the central chamber through an orifice as shown.


In the embodiment shown in FIG. 8C, and indicated at 146, air is drawn into the upstream end of the central chamber 148 through an upstream orifice 149, and is drawn into the downstream end of the chamber through a bypass orifice 150. The two orifices are dimensioned so that air drawn into the device by the user distributes at a predetermined ratio, corresponding roughly to the desired ratio of P/B (see FIG. 2A) for a normal breath intake.


It will be appreciated from the above that the gas-control valve in the device, and/or the bypass valve may include a valve that has an active gas-control element, or may be an orifice dimensioned to admit gas at a desired gas-flow rate, under conditions of selected gas pressure differential.


From the forgoing, it can be appreciated how various objects and features of the invention have been met. For use in drug inhalation, the device reproducibly produces particles having selected MMAD sizes either in the 1-3.5 μm range, or in the 10-100 nm range, achieved by controlling air flow rates through the device and the timing of airflow with respect to vapor production. Because of the rapid vapor production, and where necessary, because of the drug film thickness, the condensation particles are substantially pure, i.e., free of degradation products. The device is simple to operate, requiring little or no practice by the user to achieve desired aerosol delivery, and relatively simple in construction and operation.


Although the invention has been described with reference to particular embodiments, it will be appreciated that various changes and modifications may be made without departing from the invention.

Claims
  • 1. A device for delivering a drug by inhalation, comprising: a) a chamber having upstream and downstream openings;b) a drug supply unit that produces a drug vapor in a region of said chamber between said upstream and downstream openings;c) a gas-flow control valve upstream of said region that limits gas flow from a user's breath intake through said region to a selected flow rate or flow rate range, effective to condense said drug vapor to form an aerosol;d) a bypass orifice communicating with said chamber at a point of communication, said bypass orifice being configured to allow bypass gas to enter said chamber under conditions of inhalation actuated selected pressure differential across said bypass orifice, the point of communication preventing the bypass gas from significantly varying the selected flow rate or flow rate range through said region; ande) an actuation switch for causing said drug supply unit to produce said drug vapor.
  • 2. The device of claim 1, wherein said drug supply unit is contained within said chamber.
  • 3. The device of claim 1, wherein said drug supply unit comprises a heat source and a drug coated substrate.
  • 4. The device of claim 1, wherein drug vapor production is initiated when said selected flow rate or flow rate range is reached.
  • 5. The device of claim 1, wherein drug vapor production is initiated after said selected flow rate or flow rate range is reached.
  • 6. The device of claim 1, wherein said gas-flow control valve comprises an active gas-control element.
  • 7. The device of claim 1, wherein said gas-flow control valve is an orifice.
  • 8. The device of claim 1, wherein said actuation switch comprises a thermistor that is responsive to heat-dissipative effects of gas flow through said chamber.
  • 9. The device of claim 1, wherein said point of communication is downstream of said region.
  • 10. The device of claim 1, further comprising a bypass channel in fluid communication with said bypass orifice.
  • 11. The device of claim 1, further comprising a gas flow sensor.
  • 12. The device of claim 1, further comprising an active gas-control element operatively associated with the bypass orifice.
  • 13. The device of claim 1, further comprising a valve operatively associated with the bypass orifice.
  • 14. The device of claim 1, wherein said device comprises a plurality of bypass orifices.
  • 15. The device of claim 1, further comprising the downstream opening being configured for a user to draw air through the chamber by mouth, the bypass orifice being configured to offset a decrease in airflow produced by the gas control valve as a user draws air into the chamber.
  • 16. The device of claim 1 wherein said device is configured to be handheld.
  • 17. A device for delivering a drug by inhalation, comprising: a) a chamber having upstream and downstream ends;b) a drug supply unit that produces drug vapor in a region of said chamber between said upstream and downstream ends;c) an upstream orifice communicating with said chamber upstream of said region that limits gas flow from a user's breath intake through said region to a selected flow rate or flow rate range, effective to condense said drug vapor to form an aerosol;d) a bypass orifice communicating with said chamber downstream of said region that allows gas to enter said chamber under conditions of inhalation actuated selected pressure differential across said bypass orifice; ande) an actuation switch for causing said drug supply unit to produce drug vapor.
  • 18. The device of claim 17, wherein said drug supply unit is contained within said chamber.
  • 19. The device of claim 17, wherein said drug supply unit further comprises a heat source and a drug coated substrate.
  • 20. The device of claim 17, wherein drug vapor production is initiated when said selected flow rate or flow rate range is reached.
  • 21. The device of claim 17, wherein drug vapor production is initiated after said selected flow rate or flow rate range is reached.
  • 22. The device of claim 17, wherein said actuation switch comprises a thermistor that is responsive to heat-dissipative effects of gas flow through said chamber.
  • 23. The device of claim 17, further comprising a bypass channel communicating with said bypass orifice.
  • 24. The device of claim 17, further comprising a gas flow sensor.
  • 25. The device of claim 17, wherein said device comprises a plurality of bypass orifices.
  • 26. A device for delivering a drug by inhalation, comprising: a) a chamber having upstream and downstream openings;b) a drug supply unit that produces a drug vapor in communication with a condensation region of said chamber between said upstream and downstream openings;c) a gas-flow control valve upstream of said drug supply unit that allows gas from a user's breath intake to enter said condensation region at a selected flow rate or flow rate range to produce a condensation aerosol of a select particulate size range;d) a bypass orifice communicating with said chamber downstream of said gas-flow control valve at a location that allows gas to enter said chamber under conditions of inhalation actuated selected pressure differential across said bypass orifice without significantly varying the selected flow rate; ande) an actuation switch for causing said drug supply unit to produce said drug vapor.
  • 27. The device of claim 26, wherein said drug supply unit is contained within said chamber.
  • 28. The device of claim 26, wherein said drug supply unit comprises a heat source and a drug coated substrate.
  • 29. The device of claim 26, wherein drug vapor production is initiated when gas flow through said region reaches the selected flow rate or flow rate range.
  • 30. The device of claim 26, wherein drug vapor production is initiated after gas flow through said region reaches the selected flow rate or flow rate range.
  • 31. The device of claim 26, wherein said gas-flow control valve comprises an active gas-control element.
  • 32. The device of claim 26, wherein said gas-flow control valve is an orifice.
  • 33. The device of claim 26, wherein said actuation switch comprises a thermistor that is responsive to heat-dissipative effects of gas flow through said chamber.
  • 34. The device of claim 26, wherein said bypass orifice communicates with said chamber downstream of said condensation region.
  • 35. The device of claim 26, further comprising a bypass channel communicating with said bypass orifice.
  • 36. The device of claim 26, further comprising a gas flow sensor.
  • 37. The device of claim 26, further comprising an active gas-control element operatively associated with said bypass orifice.
  • 38. The device of claim 26, further comprising a bypass valve operatively associated with the bypass orifice.
  • 39. The device of claim 26, wherein said device comprises a plurality of bypass orifices.
  • 40. The device of claim 26, further comprising the downstream opening being configured for a user to draw air through the chamber by mouth, the bypass orifice being configured to offset a decrease in airflow produced by the gas control valve as a user draws air into the chamber.
  • 41. A device for delivering a drug by inhalation, comprising: a) a chamber having upstream and downstream ends;b) a drug supply unit that produces drug vapor in communication with a condensation region of said chamber between said upstream and downstream ends;c) an upstream orifice communicating with said chamber upstream of said condensation region that allows gas from a user's breath intake to enter said condensation region at a selected flow rate or flow rate range to produce a condensation aerosol of a select particle size range;(d) a bypass orifice communicating with said chamber downstream of said upstream orifice at a location that allows gas to enter said chamber under conditions of inhalation actuated selected gas pressure differential across said bypass orifice without significantly varying the selected flow rate; andd) an actuation switch for causing said drug supply unit to produce drug vapor.
  • 42. The device of claim 41, wherein said drug supply unit is contained within said chamber.
  • 43. The device of claim 41, wherein said drug supply unit further comprises a heat source and a drug coated substrate.
  • 44. The device of claim 41, wherein drug vapor production is initiated when gas flow through said region reaches a selected flow rate or flow rate range, effective to condense said drug vapor to form an aerosol.
  • 45. The device of claim 41, wherein drug vapor production is initiated after gas flow through said region reaches the selected flow rate or flow rate range.
  • 46. The device of claim 41, wherein said actuation switch comprises a thermistor that is responsive to heat-dissipative effects of gas flow through said chamber.
  • 47. The device of claim 41, wherein said bypass orifice communicates with said chamber downstream of said condensation region.
  • 48. The device of claim 41, further comprising a bypass channel communicating with said bypass orifice.
  • 49. The device of claim 41, further comprising a gas flow sensor.
  • 50. The device of claim 41, wherein said device comprises a plurality of bypass orifices.
  • 51. The device of claim 41, further comprising a bypass valve operatively associated with the bypass orifice.
Parent Case Info

This application claims the benefit of U.S. provisional application Ser. No. 60/429,776 filed Nov. 27, 2002, for “Method and Apparatus for Controlling Flow of Gas over a Composition,” and U.S. provisional application Ser. No. 60/429,586, filed Nov. 27, 2002 for “Flow-Actuated Medical Device.” Both of these applications are incorporated herein by reference in their entirety.

US Referenced Citations (551)
Number Name Date Kind
1239634 Stuart Sep 1917 A
1535486 Lundy Apr 1925 A
1803334 Lehmann May 1931 A
1864980 Curran Jun 1932 A
2084299 Borden Jun 1937 A
2086140 Silten Jul 1937 A
2230753 Klavehn et al. Feb 1941 A
2230754 Klavehn et al. Feb 1941 A
2243669 Clyne May 1941 A
2309846 Holm Feb 1943 A
2469656 Lienert May 1949 A
2714649 Critzer Aug 1955 A
2741812 Andre Apr 1956 A
2761055 Ike Aug 1956 A
2887106 Robinson May 1959 A
2898649 Murray Aug 1959 A
2902484 Horclois Sep 1959 A
3043977 Morowitz Jul 1962 A
3080624 Webber, III Mar 1963 A
3164600 Janssen et al. Jan 1965 A
3169095 Thiel et al. Feb 1965 A
3200819 Gilbert Aug 1965 A
3219533 Mullins Nov 1965 A
3282729 Richardson et al. Nov 1966 A
3296249 Bell Jan 1967 A
3299185 Oda et al. Jan 1967 A
3371085 Reeder et al. Feb 1968 A
3393197 Pachter Jul 1968 A
3433791 Bentley et al. Mar 1969 A
3560607 Hartley et al. Feb 1971 A
3701782 Hester Oct 1972 A
3749547 Gregory et al. Jul 1973 A
3763347 Whitaker et al. Oct 1973 A
3773995 Pachter et al. Nov 1973 A
3831606 Damani Aug 1974 A
3842828 Bird Oct 1974 A
3847650 Gregory et al. Nov 1974 A
3864326 Babington Feb 1975 A
3894040 Buzby, Jr. Jul 1975 A
3909463 Hartman Sep 1975 A
3930796 Haensel Jan 1976 A
3943941 Boyd et al. Mar 1976 A
3949743 Shanbrom Apr 1976 A
3971377 Damani Jul 1976 A
3982095 Robinson Sep 1976 A
3987052 Hester, Jr. Oct 1976 A
4008723 Borthwick et al. Feb 1977 A
4020379 Manning Apr 1977 A
4045156 Chu et al. Aug 1977 A
4079742 Rainer et al. Mar 1978 A
4104210 Coran et al. Aug 1978 A
4121583 Chen Oct 1978 A
4141369 Burruss Feb 1979 A
4160765 Weinstock Jul 1979 A
4166087 Cline et al. Aug 1979 A
4183912 Rosenthale Jan 1980 A
4184099 Lindauer et al. Jan 1980 A
4190654 Gherardi et al. Feb 1980 A
4198200 Fonda et al. Apr 1980 A
RE30285 Babington May 1980 E
4219031 Rainer et al. Aug 1980 A
4229447 Porter Oct 1980 A
4229931 Schlueter et al. Oct 1980 A
4232002 Nogrady Nov 1980 A
4236544 Osaka Dec 1980 A
4251525 Weinstock Feb 1981 A
4276243 Partus Jun 1981 A
4280629 Slaughter Jul 1981 A
4284089 Ray Aug 1981 A
4286604 Ehretsmann et al. Sep 1981 A
4303083 Burruss, Jr. Dec 1981 A
4340072 Bolt et al. Jul 1982 A
4346059 Spector Aug 1982 A
4347855 Lanzillotti et al. Sep 1982 A
4376767 Sloan Mar 1983 A
4391285 Burnett et al. Jul 1983 A
4423071 Chignac et al. Dec 1983 A
4474191 Steiner Oct 1984 A
4484576 Albarda Nov 1984 A
4508726 Coleman Apr 1985 A
4523589 Krauser Jun 1985 A
4556539 Spector Dec 1985 A
4566451 Badewien Jan 1986 A
4588425 Usry et al. May 1986 A
4588721 Mahan May 1986 A
4591615 Aldred et al. May 1986 A
4605552 Fritschi Aug 1986 A
4627963 Olson Dec 1986 A
4647428 Gyulay Mar 1987 A
4647433 Spector Mar 1987 A
4654370 Marriott, III et al. Mar 1987 A
4683231 Glassman Jul 1987 A
4693868 Katsuda et al. Sep 1987 A
4708151 Shelar Nov 1987 A
4714082 Banerjee et al. Dec 1987 A
4722334 Blackmer et al. Feb 1988 A
4734560 Bowen Mar 1988 A
4735217 Gerth et al. Apr 1988 A
4735358 Morita et al. Apr 1988 A
4753758 Miller Jun 1988 A
4755508 Bock et al. Jul 1988 A
4756318 Clearman et al. Jul 1988 A
4765347 Sensabaugh, Jr. et al. Aug 1988 A
4771795 White et al. Sep 1988 A
4774971 Vieten Oct 1988 A
4793365 Sensabaugh, Jr. et al. Dec 1988 A
4793366 Hill Dec 1988 A
4800903 Ray et al. Jan 1989 A
4801411 Wellinghoff et al. Jan 1989 A
4814161 Jinks et al. Mar 1989 A
4819665 Roberts et al. Apr 1989 A
4848374 Chard et al. Jul 1989 A
4852561 Sperry Aug 1989 A
4853517 Bowen et al. Aug 1989 A
4854331 Banerjee et al. Aug 1989 A
4858630 Banerjee et al. Aug 1989 A
4863720 Burghart et al. Sep 1989 A
4881541 Eger et al. Nov 1989 A
4881556 Clearman et al. Nov 1989 A
4889850 Thornfeldt et al. Dec 1989 A
4892109 Strubel Jan 1990 A
4895719 Radhakrishnun et al. Jan 1990 A
4906417 Gentry Mar 1990 A
4911157 Miller Mar 1990 A
4917119 Potter et al. Apr 1990 A
4917120 Hill Apr 1990 A
4917830 Ortiz et al. Apr 1990 A
4922901 Brooks et al. May 1990 A
4924883 Perfetti et al. May 1990 A
4928714 Shannon May 1990 A
4935624 Henion et al. Jun 1990 A
4941483 Ridings et al. Jul 1990 A
4947874 Brooks et al. Aug 1990 A
4947875 Brooks et al. Aug 1990 A
4950664 Goldberg Aug 1990 A
4955945 Weick Sep 1990 A
4959380 Wilson Sep 1990 A
4963289 Ortiz et al. Oct 1990 A
4968885 Willoughby Nov 1990 A
4984158 Hillsman Jan 1991 A
4989619 Clearman et al. Feb 1991 A
5016425 Weick May 1991 A
5017575 Golwyn May 1991 A
5019122 Clearman et al. May 1991 A
5020548 Farrier et al. Jun 1991 A
5027836 Shannon et al. Jul 1991 A
5033483 Clearman et al. Jul 1991 A
5038769 Krauser Aug 1991 A
5042509 Banerjee et al. Aug 1991 A
5049389 Radhakrishnun Sep 1991 A
5060666 Clearman et al. Oct 1991 A
5060667 Strubel Oct 1991 A
5060671 Counts et al. Oct 1991 A
5067499 Banerjee et al. Nov 1991 A
5072726 Mazloomdoost et al. Dec 1991 A
5076292 Sensabaugh, Jr. et al. Dec 1991 A
5093894 Deevi et al. Mar 1992 A
5095921 Loose et al. Mar 1992 A
5099861 Clearman et al. Mar 1992 A
5105831 Banerjee et al. Apr 1992 A
5109180 Boultinghouse et al. Apr 1992 A
5112598 Biesalski May 1992 A
5118494 Schultz et al. Jun 1992 A
5119834 Shannon et al. Jun 1992 A
5126123 Johnson Jun 1992 A
5133368 Neumann et al. Jul 1992 A
5135009 Muller et al. Aug 1992 A
5137034 Perfetti et al. Aug 1992 A
5144962 Counts et al. Sep 1992 A
5146915 Montgomery Sep 1992 A
5149538 Granger et al. Sep 1992 A
5156170 Clearman et al. Oct 1992 A
5160664 Liu Nov 1992 A
5164740 Ivri Nov 1992 A
5166202 Schweizer Nov 1992 A
5167242 Turner et al. Dec 1992 A
5177071 Freidinger et al. Jan 1993 A
5179966 Losee et al. Jan 1993 A
5186164 Raghuprasad Feb 1993 A
5192548 Velasquez et al. Mar 1993 A
5224498 Deevi et al. Jul 1993 A
5226411 Levine Jul 1993 A
5229120 DeVincent Jul 1993 A
5229382 Chakrabarti et al. Jul 1993 A
5240922 O'Neill Aug 1993 A
5249586 Morgan et al. Oct 1993 A
5255674 Oftedal et al. Oct 1993 A
5261424 Sprinkel, Jr. Nov 1993 A
5264433 Sato et al. Nov 1993 A
5269327 Counts et al. Dec 1993 A
5284133 Burns et al. Feb 1994 A
5285798 Banerjee et al. Feb 1994 A
5292499 Evans et al. Mar 1994 A
5322075 Deevi et al. Jun 1994 A
5333106 Lanpher et al. Jul 1994 A
5345951 Serrano et al. Sep 1994 A
5357984 Farrier et al. Oct 1994 A
5363842 Mishelevich et al. Nov 1994 A
5364838 Rubsamen Nov 1994 A
5366770 Wang Nov 1994 A
5372148 McCafferty et al. Dec 1994 A
5376386 Ganderton et al. Dec 1994 A
5388574 Ingebrethsen Feb 1995 A
5391081 Lampotang et al. Feb 1995 A
5399574 Robertson et al. Mar 1995 A
5400808 Turner et al. Mar 1995 A
5400969 Keene Mar 1995 A
5402517 Gillett et al. Mar 1995 A
5408574 Deevi et al. Apr 1995 A
5436230 Soudant et al. Jul 1995 A
5451408 Mezei et al. Sep 1995 A
5455043 Fischel-Ghodsian Oct 1995 A
5456247 Shilling et al. Oct 1995 A
5456677 Spector Oct 1995 A
5457100 Daniel Oct 1995 A
5457101 Greenwood et al. Oct 1995 A
5459137 Andrasi et al. Oct 1995 A
5462740 Evenstad et al. Oct 1995 A
5468936 Deevi et al. Nov 1995 A
5479948 Counts et al. Jan 1996 A
5501236 Hill et al. Mar 1996 A
5505214 Collins et al. Apr 1996 A
5507277 Rubsamen et al. Apr 1996 A
5511726 Greenspan et al. Apr 1996 A
5519019 Andrasi et al. May 1996 A
5525329 Snyder et al. Jun 1996 A
5537507 Mariner et al. Jul 1996 A
5538020 Farrier et al. Jul 1996 A
5540959 Wang Jul 1996 A
5543434 Weg Aug 1996 A
5544646 Lloyd et al. Aug 1996 A
5564442 MacDonald et al. Oct 1996 A
5565148 Pendergrass Oct 1996 A
5577156 Costello Nov 1996 A
5584701 Lampotang et al. Dec 1996 A
5586550 Ivri et al. Dec 1996 A
5591409 Watkins Jan 1997 A
5592934 Thwaites Jan 1997 A
5593792 Farrier et al. Jan 1997 A
5605146 Sarela Feb 1997 A
5605897 Beasley, Jr. et al. Feb 1997 A
5607691 Hale et al. Mar 1997 A
5613504 Collins et al. Mar 1997 A
5613505 Campbell et al. Mar 1997 A
5619984 Hodson et al. Apr 1997 A
5622944 Hale et al. Apr 1997 A
5627178 Chakrabarti et al. May 1997 A
5649554 Sprinkel Jul 1997 A
5655523 Hodson et al. Aug 1997 A
5656255 Jones Aug 1997 A
5660166 Lloyd et al. Aug 1997 A
5666977 Higgins et al. Sep 1997 A
5690809 Subramaniam et al. Nov 1997 A
5694919 Rubsamen et al. Dec 1997 A
5718222 Lloyd et al. Feb 1998 A
5724957 Rubsamen et al. Mar 1998 A
5725756 Subramaniam et al. Mar 1998 A
5733572 Unger et al. Mar 1998 A
5735263 Rubsamen et al. Apr 1998 A
5738865 Baichwal et al. Apr 1998 A
5743250 Gonda et al. Apr 1998 A
5743251 Howell et al. Apr 1998 A
5744469 Tran Apr 1998 A
5747001 Wiedmann et al. May 1998 A
5756449 Andersen et al. May 1998 A
5758637 Ivri et al. Jun 1998 A
5767117 Moskowitz et al. Jun 1998 A
5769621 Early et al. Jun 1998 A
5770222 Unger et al. Jun 1998 A
5771882 Psaros et al. Jun 1998 A
5776928 Beasley, Jr. Jul 1998 A
5804212 Illum Sep 1998 A
5809997 Wolf Sep 1998 A
5817656 Beasley, Jr. et al. Oct 1998 A
5819756 Mielordt Oct 1998 A
5823178 Lloyd et al. Oct 1998 A
5823180 Zapol Oct 1998 A
5829436 Rubsamen et al. Nov 1998 A
5833891 Subramaniam et al. Nov 1998 A
5840246 Hammons et al. Nov 1998 A
5855564 Ruskewicz Jan 1999 A
5855913 Hanes et al. Jan 1999 A
5865185 Collins et al. Feb 1999 A
5874064 Edwards et al. Feb 1999 A
5874481 Weers et al. Feb 1999 A
5875776 Vaghefi Mar 1999 A
5878752 Adams et al. Mar 1999 A
5884620 Gonda et al. Mar 1999 A
5890908 Lampotang et al. Apr 1999 A
5894841 Voges Apr 1999 A
5904900 Bleuse et al. May 1999 A
5906202 Schuster et al. May 1999 A
5906811 Hersh May 1999 A
5907075 Subramaniam et al. May 1999 A
5910301 Farr et al. Jun 1999 A
5915378 Lloyd et al. Jun 1999 A
5918595 Olsson Jul 1999 A
5928520 Haumesser Jul 1999 A
5929093 Pang et al. Jul 1999 A
5934272 Lloyd et al. Aug 1999 A
5934289 Watkins et al. Aug 1999 A
5935604 Illum Aug 1999 A
5938117 Ivri Aug 1999 A
5939100 Albrechtsen et al. Aug 1999 A
5941240 Gonda et al. Aug 1999 A
5944012 Pera Aug 1999 A
5957124 Lloyd et al. Sep 1999 A
5960792 Lloyd et al. Oct 1999 A
5970973 Gonda et al. Oct 1999 A
5971951 Ruskewicz Oct 1999 A
5985309 Edwards et al. Nov 1999 A
5993805 Sutton et al. Nov 1999 A
6004516 Rasouli et al. Dec 1999 A
6004970 O'Malley et al. Dec 1999 A
6008214 Kwon et al. Dec 1999 A
6008216 Chakrabarti et al. Dec 1999 A
6013050 Bellhouse et al. Jan 2000 A
6014969 Lloyd et al. Jan 2000 A
6014970 Ivri et al. Jan 2000 A
6041777 Faithfull et al. Mar 2000 A
6044777 Walsh Apr 2000 A
6048550 Chan et al. Apr 2000 A
6048857 Ellinwood, Jr. et al. Apr 2000 A
6050260 Daniell et al. Apr 2000 A
6051257 Kodas et al. Apr 2000 A
6051566 Bianco Apr 2000 A
6053176 Adams et al. Apr 2000 A
RE36744 Goldberg Jun 2000 E
6085026 Hammons et al. Jul 2000 A
6089857 Matsuura et al. Jul 2000 A
6090212 Mahawili Jul 2000 A
6090403 Block et al. Jul 2000 A
6095134 Sievers et al. Aug 2000 A
6095153 Kessler et al. Aug 2000 A
6098620 Lloyd et al. Aug 2000 A
6102036 Slutsky et al. Aug 2000 A
6113795 Subramaniam et al. Sep 2000 A
6117866 Bondinell et al. Sep 2000 A
6125853 Susa et al. Oct 2000 A
6126919 Stefely et al. Oct 2000 A
6131566 Ashurst et al. Oct 2000 A
6131570 Schuster et al. Oct 2000 A
6133327 Kimura et al. Oct 2000 A
6135369 Prendergast et al. Oct 2000 A
6136295 Edwards et al. Oct 2000 A
6138683 Hersh et al. Oct 2000 A
6140323 Ellinwood, Jr. et al. Oct 2000 A
6143277 Ashurst et al. Nov 2000 A
6143746 Daugan et al. Nov 2000 A
6149892 Britto Nov 2000 A
6155268 Takeuchi Dec 2000 A
6158431 Poole Dec 2000 A
6167880 Gonda et al. Jan 2001 B1
6178969 St. Charles Jan 2001 B1
6234167 Cox et al. May 2001 B1
6241969 Saidi et al. Jun 2001 B1
6250301 Pate Jun 2001 B1
6255334 Sands Jul 2001 B1
6263872 Schuster et al. Jul 2001 B1
6264922 Wood et al. Jul 2001 B1
6284287 Sarlikiotis et al. Sep 2001 B1
6299900 Reed et al. Oct 2001 B1
6300710 Nakamori Oct 2001 B1
6306431 Zhang et al. Oct 2001 B1
6309668 Bastin et al. Oct 2001 B1
6309986 Flashinski et al. Oct 2001 B1
6313176 Ellinwood, Jr. et al. Nov 2001 B1
6325475 Hayes et al. Dec 2001 B1
6376550 Raber et al. Apr 2002 B1
6390453 Frederickson et al. May 2002 B1
6408854 Gonda et al. Jun 2002 B1
6413930 Ratti et al. Jul 2002 B1
6420351 Tsai et al. Jul 2002 B1
6431166 Gonda et al. Aug 2002 B2
6443152 Lockhart et al. Sep 2002 B1
6461591 Keller et al. Oct 2002 B1
6491233 Nichols Dec 2002 B2
6501052 Cox et al. Dec 2002 B2
6506762 Horvath et al. Jan 2003 B1
6514482 Bartus et al. Feb 2003 B1
6516796 Cox et al. Feb 2003 B1
6557552 Cox et al. May 2003 B1
6561186 Casper et al. May 2003 B2
6568390 Nichols et al. May 2003 B2
6591839 Meyer et al. Jul 2003 B2
6632047 Vinegar et al. Oct 2003 B2
6648950 Lee et al. Nov 2003 B2
6671945 Gerber et al. Jan 2004 B2
6680668 Gerber et al. Jan 2004 B2
6681769 Sprinkel et al. Jan 2004 B2
6681998 Sharpe et al. Jan 2004 B2
6682716 Hodges et al. Jan 2004 B2
6688313 Wrenn et al. Feb 2004 B2
6694975 Schuster et al. Feb 2004 B2
6701921 Sprinkel et al. Mar 2004 B2
6701922 Hindle et al. Mar 2004 B2
6715487 Nichols et al. Apr 2004 B2
6716415 Rabinowitz et al. Apr 2004 B2
6716416 Rabinowitz et al. Apr 2004 B2
6716417 Rabinowitz et al. Apr 2004 B2
6728478 Cox et al. Apr 2004 B2
6729324 Casper et al. May 2004 B2
6737042 Rabinowitz et al. May 2004 B2
6737043 Rabinowitz et al. May 2004 B2
6740307 Rabinowitz et al. May 2004 B2
6740308 Rabinowitz et al. May 2004 B2
6740309 Rabinowitz et al. May 2004 B2
6743415 Rabinowitz et al. Jun 2004 B2
6759029 Hale et al. Jul 2004 B2
6772756 Shayan Aug 2004 B2
6772757 Sprinkel, Jr. Aug 2004 B2
6776978 Rabinowitz et al. Aug 2004 B2
6779520 Genova et al. Aug 2004 B2
6780399 Rabinowitz et al. Aug 2004 B2
6780400 Rabinowitz et al. Aug 2004 B2
6783753 Rabinowitz et al. Aug 2004 B2
6797259 Rabinowitz et al. Sep 2004 B2
6803031 Rabinowitz et al. Oct 2004 B2
6805853 Rabinowitz et al. Oct 2004 B2
6805854 Hale et al. Oct 2004 B2
6814954 Rabinowitz et al. Nov 2004 B2
6814955 Rabinowitz et al. Nov 2004 B2
6855310 Rabinowitz et al. Feb 2005 B2
6884408 Rabinowitz et al. Apr 2005 B2
6994843 Rabinowitz et al. Feb 2006 B2
7005121 Rabinowitz et al. Feb 2006 B2
7005122 Hale et al. Feb 2006 B2
7008615 Rabinowitz et al. Mar 2006 B2
7008616 Rabinowitz et al. Mar 2006 B2
7011819 Hale et al. Mar 2006 B2
7011820 Rabinowitz et al. Mar 2006 B2
7014840 Hale et al. Mar 2006 B2
7014841 Rabinowitz et al. Mar 2006 B2
7018619 Rabinowitz et al. Mar 2006 B2
7018620 Rabinowitz et al. Mar 2006 B2
7018621 Hale et al. Mar 2006 B2
7022312 Rabinowitz et al. Apr 2006 B2
7029658 Rabinowitz et al. Apr 2006 B2
7033575 Rabinowitz et al. Apr 2006 B2
7040314 Nguyen et al. May 2006 B2
7045118 Rabinowitz et al. May 2006 B2
7045119 Rabinowitz et al. May 2006 B2
7048909 Rabinowitz et al. May 2006 B2
7052679 Rabinowitz et al. May 2006 B2
7052680 Rabinowitz et al. May 2006 B2
7060254 Rabinowitz et al. Jun 2006 B2
7060255 Rabinowitz et al. Jun 2006 B2
7063830 Rabinowitz et al. Jun 2006 B2
7063831 Rabinowitz et al. Jun 2006 B2
7063832 Rabinowitz et al. Jun 2006 B2
7067114 Rabinowitz et al. Jun 2006 B2
7070761 Rabinowitz et al. Jul 2006 B2
7070762 Rabinowitz et al. Jul 2006 B2
7070763 Rabinowitz et al. Jul 2006 B2
7070764 Rabinowitz et al. Jul 2006 B2
7070765 Rabinowitz et al. Jul 2006 B2
7070766 Rabinowitz et al. Jul 2006 B2
7078016 Rabinowitz et al. Jul 2006 B2
7078017 Rabinowitz et al. Jul 2006 B2
7078018 Rabinowitz et al. Jul 2006 B2
7078019 Rabinowitz et al. Jul 2006 B2
7078020 Rabinowitz et al. Jul 2006 B2
7087216 Rabinowitz et al. Aug 2006 B2
7087217 Rabinowitz et al. Aug 2006 B2
7087218 Rabinowitz et al. Aug 2006 B2
7090830 Hale et al. Aug 2006 B2
7094392 Rabinowitz et al. Aug 2006 B2
7108847 Rabinowitz et al. Sep 2006 B2
7115250 Rabinowitz et al. Oct 2006 B2
7169378 Rabinowitz et al. Jan 2007 B2
7402777 Ron et al. Jul 2008 B2
20010020147 Staniforth et al. Sep 2001 A1
20010042546 Umeda et al. Nov 2001 A1
20020031480 Peart et al. Mar 2002 A1
20020037828 Wilson et al. Mar 2002 A1
20020058009 Bartus et al. May 2002 A1
20020061281 Osbakken et al. May 2002 A1
20020078955 Nichols et al. Jun 2002 A1
20020086852 Cantor Jul 2002 A1
20020097139 Gerber et al. Jul 2002 A1
20020112723 Schuster et al. Aug 2002 A1
20020117175 Kottayil et al. Aug 2002 A1
20020176841 Barker et al. Nov 2002 A1
20030004142 Prior et al. Jan 2003 A1
20030015196 Hodges et al. Jan 2003 A1
20030015197 Hale et al. Jan 2003 A1
20030032638 Kim et al. Feb 2003 A1
20030033055 McRae et al. Feb 2003 A1
20030049025 Neumann et al. Mar 2003 A1
20030051728 Lloyd et al. Mar 2003 A1
20030062042 Wensley et al. Apr 2003 A1
20030106551 Sprinkel et al. Jun 2003 A1
20030118512 Shen Jun 2003 A1
20030121906 Abbott et al. Jul 2003 A1
20030131843 Lu Jul 2003 A1
20030132219 Cox et al. Jul 2003 A1
20030138508 Novack et al. Jul 2003 A1
20030156829 Cox et al. Aug 2003 A1
20030209240 Hale et al. Nov 2003 A1
20040009128 Rabinowitz et al. Jan 2004 A1
20040016427 Byron et al. Jan 2004 A1
20040035409 Harwig et al. Feb 2004 A1
20040055504 Lee et al. Mar 2004 A1
20040081624 Nguyen et al. Apr 2004 A1
20040096402 Hodges et al. May 2004 A1
20040101481 Hale et al. May 2004 A1
20040102434 Hale et al. May 2004 A1
20040105818 Every et al. Jun 2004 A1
20040105819 Hale et al. Jun 2004 A1
20040234699 Hale et al. Nov 2004 A1
20040234914 Hale et al. Nov 2004 A1
20040234916 Hale et al. Nov 2004 A1
20050034723 Bennett et al. Feb 2005 A1
20050037506 Hale et al. Feb 2005 A1
20050079166 Damani et al. Apr 2005 A1
20050126562 Rabinowitz et al. Jun 2005 A1
20050131739 Rabinowitz et al. Jun 2005 A1
20050268911 Cross et al. Dec 2005 A1
20060032496 Hale et al. Feb 2006 A1
20060032501 Hale et al. Feb 2006 A1
20060120962 Rabinowitz et al. Jun 2006 A1
20060153779 Rabinowitz et al. Jul 2006 A1
20060177382 Rabinowitz et al. Aug 2006 A1
20060193788 Hale et al. Aug 2006 A1
20060216243 Rabinowitz et al. Sep 2006 A1
20060216244 Rabinowitz et al. Sep 2006 A1
20060233717 Hale et al. Oct 2006 A1
20060233718 Rabinowitz et al. Oct 2006 A1
20060233719 Rabinowitz et al. Oct 2006 A1
20060239936 Rabinowitz et al. Oct 2006 A1
20060246011 Rabinowitz et al. Nov 2006 A1
20060246012 Rabinowitz et al. Nov 2006 A1
20060251587 Rabinowitz et al. Nov 2006 A1
20060251588 Rabinowitz et al. Nov 2006 A1
20060257328 Rabinowitz et al. Nov 2006 A1
20060257329 Rabinowitz et al. Nov 2006 A1
20060269486 Rabinowitz et al. Nov 2006 A1
20060269487 Rabinowitz et al. Nov 2006 A1
20060280692 Rabinowitz et al. Dec 2006 A1
20060286042 Rabinowitz et al. Dec 2006 A1
20060286043 Rabinowitz et al. Dec 2006 A1
20070014737 Rabinowitz et al. Jan 2007 A1
20070028916 Hale et al. Feb 2007 A1
20070031340 Hale et al. Feb 2007 A1
20070122353 Hale et al. May 2007 A1
20070140982 Every et al. Jun 2007 A1
20070178052 Rabinowitz et al. Aug 2007 A1
20070286816 Hale et al. Dec 2007 A1
20080110872 Hale et al. May 2008 A1
20080175796 Rabinowitz et al. Jul 2008 A1
20080216828 Wensley Sep 2008 A1
Foreign Referenced Citations (119)
Number Date Country
2152684 Jan 1996 CA
1082365 Feb 1994 CN
1176075 Mar 1998 CN
198 54 007 May 2000 DE
0 039 369 Nov 1981 EP
0 274 431 Jul 1988 EP
0 277 519 Aug 1988 EP
0 358 114 Mar 1990 EP
0 430 559 Jun 1991 EP
0 492 485 Jul 1992 EP
0 606 486 Jul 1994 EP
0 734 719 Feb 1996 EP
0 808 635 Jul 1998 EP
0 967 214 Dec 1999 EP
1 080 720 Mar 2001 EP
1 177 793 Feb 2002 EP
921 852 May 1947 FR
2 428 068 Jan 1980 FR
502 761 Jan 1938 GB
903 866 Aug 1962 GB
1 366 041 Sep 1974 GB
2 108 390 May 1983 GB
2 122 903 Jan 1984 GB
200105 Oct 1988 HU
219392 Jun 1993 HU
WO 8500520 Feb 1985 WO
WO 8808304 Nov 1988 WO
WO 9002737 Mar 1990 WO
WO 9007333 Jul 1990 WO
WO 9107947 Jun 1991 WO
WO 9118525 Dec 1991 WO
WO 9205781 Apr 1992 WO
WO 9215353 Sep 1992 WO
WO 9219303 Nov 1992 WO
WO 9312823 Jul 1993 WO
WO 9409842 May 1994 WO
WO 9416717 Aug 1994 WO
WO 9416757 Aug 1994 WO
WO 9416759 Aug 1994 WO
WO 9417369 Aug 1994 WO
WO 9417370 Aug 1994 WO
WO 9427576 Dec 1994 WO
WO 9427653 Dec 1994 WO
WO 9531182 Nov 1995 WO
WO 9600069 Jan 1996 WO
WO 9600070 Jan 1996 WO
WO 9600071 Jan 1996 WO
WO 9609846 Apr 1996 WO
WO 9610663 Apr 1996 WO
WO 9613161 May 1996 WO
WO 9613290 May 1996 WO
WO 9613291 May 1996 WO
WO 9613292 May 1996 WO
WO 9630068 Oct 1996 WO
WO 9631198 Oct 1996 WO
WO 9637198 Nov 1996 WO
WO 9716181 May 1997 WO
WO 9717948 May 1997 WO
WO 9723221 Jul 1997 WO
WO 9727804 Aug 1997 WO
WO 9731691 Sep 1997 WO
WO 9735562 Oct 1997 WO
WO 9736574 Oct 1997 WO
WO 9740819 Nov 1997 WO
WO 9749690 Dec 1997 WO
WO 9802186 Jan 1998 WO
WO 9816205 Apr 1998 WO
WO 9822170 May 1998 WO
WO 9829110 Jul 1998 WO
WO 9831346 Jul 1998 WO
WO 9834595 Aug 1998 WO
WO 9836651 Aug 1998 WO
WO 9837896 Sep 1998 WO
WO 9904797 Feb 1999 WO
WO 9916419 Apr 1999 WO
WO 9924433 May 1999 WO
WO 9937347 Jul 1999 WO
WO 9937625 Jul 1999 WO
WO 9944664 Sep 1999 WO
WO 9955362 Nov 1999 WO
WO 9959710 Nov 1999 WO
WO 9964094 Dec 1999 WO
WO 0000176 Jan 2000 WO
WO 0000215 Jan 2000 WO
WO 0000244 Jan 2000 WO
WO 0019991 Apr 2000 WO
WO 0027359 May 2000 WO
WO 0027363 May 2000 WO
WO 0028979 May 2000 WO
WO 0029053 May 2000 WO
WO 0029167 May 2000 WO
WO 0035417 Jun 2000 WO
WO 0038618 Jul 2000 WO
WO 0044350 Aug 2000 WO
WO 0044730 Aug 2000 WO
WO 0047203 Sep 2000 WO
WO 0051491 Sep 2000 WO
WO 0064940 Nov 2000 WO
WO 0066084 Nov 2000 WO
WO 0066106 Nov 2000 WO
WO 0066206 Nov 2000 WO
WO 0072827 Dec 2000 WO
WO 0076673 Dec 2000 WO
WO 0105459 Jan 2001 WO
WO 0113957 Mar 2001 WO
WO 0117568 Mar 2001 WO
WO 0119528 Mar 2001 WO
WO 0129011 Apr 2001 WO
WO 0132144 May 2001 WO
WO 0141732 Jun 2001 WO
WO 0143801 Jun 2001 WO
WO 0166064 Sep 2001 WO
WO 0195903 Dec 2001 WO
WO 0200198 Jan 2002 WO
WO 0224158 Mar 2002 WO
WO 02051466 Jul 2002 WO
WO 02056866 Jul 2002 WO
WO 02094234 Nov 2002 WO
WO 03037412 May 2003 WO
Related Publications (1)
Number Date Country
20040099266 A1 May 2004 US
Provisional Applications (2)
Number Date Country
60429776 Nov 2002 US
60429586 Nov 2002 US